Recent advances in understanding and treating immunoglobulin light chain amyloidosis [version 1; referees: 2 approved]

• Main Authors: Talha Badar, Anita D'Souza, Parameswaran Hari
• Format: Article
• Language: English
• Published: F1000 Research Ltd 2018-08-01
• Series: F1000Research
• Online Access: https://f1000research.com/articles/7-1348/v1

Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction. Owing to its diverse clinical presentations and a tendency to mimic common medical conditions, AL amyloidosis is often diagnosed late and results in dismal outcomes. Early referral to a specialized center with expertise in management of AL amyloidosis is always recommended. The availability of sensitive biomarkers and novel therapies is reforming our approach to how we manage AL amyloidosis. Treatment for patients with AL amyloidosis should be risk-adapted and customized on the basis of individual patient characteristics. In the future, approaches directed at amyloid fibril clearance in combination with agents that target plasma cells will be needed both to eradicate the malignant clone and to establish organ responses.